0.3376
price up icon7.83%   0.0246
 
loading
Precedente Chiudi:
$0.313
Aprire:
$0.32
Volume 24 ore:
3.80M
Relative Volume:
3.12
Capitalizzazione di mercato:
$11.70M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+21.80%
1M Prestazione:
-25.20%
6M Prestazione:
-80.82%
1 anno Prestazione:
-87.83%
Intervallo 1D:
Value
$0.32
$0.439
Intervallo di 1 settimana:
Value
$0.2551
$0.439
Portata 52W:
Value
$0.2026
$4.06

Nkgen Biotech Inc Stock (NKGN) Company Profile

Name
Nome
Nkgen Biotech Inc
Name
Telefono
(949) 396-6830
Name
Indirizzo
3001 DAIMLER ST,, SANTA ANA
Name
Dipendente
63
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-12
Name
Ultimi documenti SEC
Name
NKGN's Discussions on Twitter

Confronta NKGN con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
NKGN 0.3376 11.70M 0 0 0 0.00
VRTX 449.73 115.43B 10.63B -479.80M -1.35B 13.33
REGN 747.20 82.04B 13.85B 4.65B 3.32B 35.06
ARGX 598.89 35.30B 1.86B -40.29M -1.28B -4.16
ALNY 246.91 32.04B 2.09B -332.26M 16.06M -4.14
BNTX 108.03 24.89B 3.30B -501.07M 1.03B 11.54

Nkgen Biotech Inc Borsa (NKGN) Ultime notizie

pulisher
Nov 18, 2024

OC500 2024: Paul Y. Song - Orange County Business Journal

Nov 18, 2024
pulisher
Nov 14, 2024

NKGen Biotech (NYSE:NKGN) versus Relay Therapeutics (NASDAQ:RLAY) Financial Contrast - Defense World

Nov 14, 2024
pulisher
Nov 08, 2024

Midday Stock Roundup: Indie Semiconductor Up 43% - Orange County Business Journal

Nov 08, 2024
pulisher
Oct 29, 2024

NKGen Flat on Presentation of Alzheimer's Treatment - Baystreet.ca

Oct 29, 2024
pulisher
Oct 29, 2024

NKGen Biotech Presents Phase 1/2a Troculeucel Data in Alzheimer's Disease at the 17th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference - The Manila Times

Oct 29, 2024
pulisher
Oct 29, 2024

NKGen Biotech Presents Phase 1/2a Troculeucel Data in - GlobeNewswire

Oct 29, 2024
pulisher
Oct 29, 2024

NKGen Biotech Presents Phase 1/2a Troculeucel Data in Alzheimer’s Disease at the 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference - StockTitan

Oct 29, 2024
pulisher
Oct 24, 2024

NKGen Biotech avoids Nasdaq delisting with regained compliance - Investing.com India

Oct 24, 2024
pulisher
Oct 16, 2024

Navigating NKGN Stock: NKGen Biotech Inc Journey - The InvestChronicle

Oct 16, 2024
pulisher
Oct 16, 2024

Post-Trade Analysis: NKGen Biotech Inc (NKGN) Slides -6.54, Closing at 0.23 - The Dwinnex

Oct 16, 2024
pulisher
Oct 15, 2024

NKGen Biotech Announces Upcoming Presentation at the 16th World Stroke Congress (WSC 2024) - The Manila Times

Oct 15, 2024
pulisher
Oct 10, 2024

NKGen Biotech undergoes dilutive stock issuance By Investing.com - Investing.com Canada

Oct 10, 2024
pulisher
Oct 10, 2024

NKGen Biotech undergoes dilutive stock issuance - Investing.com India

Oct 10, 2024
pulisher
Oct 08, 2024

NKGN stock touches 52-week low at $0.35 amid market challenges - Investing.com Australia

Oct 08, 2024
pulisher
Oct 08, 2024

NKGen Biotech Announces Poster Presentations at the 17th - GlobeNewswire

Oct 08, 2024
pulisher
Oct 08, 2024

NKGen Biotech Announces Poster Presentations at the 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference - StockTitan

Oct 08, 2024
pulisher
Oct 07, 2024

Market Watch Highlights: NKGen Biotech Inc (NKGN) Ends on an Upturn Note at 0.40 - The Dwinnex

Oct 07, 2024
pulisher
Oct 04, 2024

NKGen Biotech directors resign after a year of service By Investing.com - Investing.com Australia

Oct 04, 2024
pulisher
Oct 04, 2024

NKGen Biotech appoints new directors to its board By Investing.com - Investing.com South Africa

Oct 04, 2024
pulisher
Oct 04, 2024

NKGen Biotech appoints new directors to its board - Investing.com India

Oct 04, 2024
pulisher
Oct 04, 2024

NKGen Biotech Welcomes New Directors and Assigns Committees - TipRanks

Oct 04, 2024
pulisher
Oct 03, 2024

NKGen Biotech directors resign after a year of service - Investing.com India

Oct 03, 2024
pulisher
Oct 03, 2024

NKGen Biotech Announces Leadership Shuffle on Anniversary - TipRanks

Oct 03, 2024
pulisher
Sep 28, 2024

NKGen Biotech faces potential Nasdaq delisting By Investing.com - Investing.com South Africa

Sep 28, 2024
pulisher
Sep 27, 2024

NKGen Biotech faces potential Nasdaq delisting - Investing.com

Sep 27, 2024
pulisher
Sep 27, 2024

Midday Stock Roundup: Indie Shares Down 5% - Orange County Business Journal

Sep 27, 2024
pulisher
Sep 24, 2024

Analysts agree that Kenvue's Neutrogena needs a face-lift (KVUE) - Seeking Alpha

Sep 24, 2024
pulisher
Sep 24, 2024

Nkarta Inc (NKTX)’s highs and lows: A closer look at its stock price fluctuations - US Post News

Sep 24, 2024
pulisher
Sep 23, 2024

Top investors say Krystal Biotech Inc (KRYS) ticks everything they need - SETE News

Sep 23, 2024
pulisher
Sep 23, 2024

Investor’s Delight: Krystal Biotech Inc (KRYS) Closes Weak at 184.17, Down -0.17 - The Dwinnex

Sep 23, 2024
pulisher
Sep 23, 2024

Market Momentum Report: Nkarta Inc (NKTX)’s Negative Close at 5.21 - The Dwinnex

Sep 23, 2024
pulisher
Sep 23, 2024

Raymond James Upgrades Nkarta Inc (NKTX) to a Strong buy from an Outperform - Knox Daily

Sep 23, 2024
pulisher
Sep 23, 2024

70,000 Shares in Neurogene Inc. (NASDAQ:NGNE) Purchased by Integral Health Asset Management LLC - Defense World

Sep 23, 2024
pulisher
Sep 21, 2024

Krystal Biotech, Inc. (KRYS): Promising Pipeline or Risky Gamble? - Insider Monkey

Sep 21, 2024
pulisher
Sep 21, 2024

ASB Consultores LLC Trims Stock Holdings in PENN Entertainment, Inc. (NASDAQ:PENN) - Defense World

Sep 21, 2024
pulisher
Sep 20, 2024

NKGen Biotech issues shares for debt conversion - Investing.com

Sep 20, 2024
pulisher
Sep 20, 2024

What was NKGen Biotech Inc (NKGN)’s performance in the last session? - US Post News

Sep 20, 2024
pulisher
Sep 19, 2024

NKGN stock touches 52-week low at $0.45 amid market challenges - Investing.com

Sep 19, 2024
pulisher
Sep 18, 2024

NKGN’s Stock Market Adventure: -82.15% YTD Growth Amidst Volatility - The InvestChronicle

Sep 18, 2024
pulisher
Sep 18, 2024

Market Momentum: NKGen Biotech Inc (NKGN) Registers a -34.09 Decrease, Closing at 0.49 - The Dwinnex

Sep 18, 2024
pulisher
Sep 17, 2024

NKGen Biotech appeals Nasdaq delisting decision - Investing.com

Sep 17, 2024
pulisher
Sep 16, 2024

NKGen Biotech faces Nasdaq delisting over market value - Investing.com India

Sep 16, 2024
pulisher
Sep 12, 2024

A closer look at NKGN’s price-to-free cash flow ratio - US Post News

Sep 12, 2024
pulisher
Sep 12, 2024

Selling Your Nano Nuclear Energy Inc. (NASDAQ: NNE) Stock? Here’s What You Need To Know - Stocks Register

Sep 12, 2024
pulisher
Sep 12, 2024

NKGen Biotech’s Positive Phase 1 Clinical Data in Moderate - GlobeNewswire

Sep 12, 2024
pulisher
Sep 12, 2024

NKGen Biotech’s Positive Phase 1 Clinical Data in Moderate Alzheimer’s Disease Advances Troculeucel into Phase 2 with First Patient Dosed in Phase 1/2a Trial - StockTitan

Sep 12, 2024
pulisher
Sep 12, 2024

NKGen Biotech amends agreement, increases share consideration By Investing.com - Investing.com Australia

Sep 12, 2024
pulisher
Sep 12, 2024

New Outlook On Intelligent Bio Solutions Inc - Stocks Register

Sep 12, 2024

Nkgen Biotech Inc Azioni (NKGN) Dati Finanziari

Non sono disponibili dati finanziari per Nkgen Biotech Inc (NKGN). Controlla altri titoli per ulteriori informazioni.

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$18.98
price up icon 1.80%
$70.68
price down icon 0.42%
$38.38
price up icon 3.49%
$369.83
price up icon 1.48%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Capitalizzazione:     |  Volume (24 ore):